Navigation Links
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Date:11/3/2008

with estimates of over 500,000 cases in the United States, and approximately 15,000 deaths caused or contributed by C. difficile.(2) The emergence of a highly virulent epidemic strain that produces much higher levels of toxins A and B has also been associated with morbidity and mortality in younger, healthier, and non-hospitalized patients.(3)

"We are delighted with these dramatic results. CDAD is a growing and serious epidemic, with twenty to fifty percent of hospitalized patients relapsing after receiving antibiotic treatment," said Donna Ambrosino, MD, Executive Director of the MBL and Professor of Pediatrics at UMMS. "The demonstration of significant protection from relapse indicates that treatment with monoclonal antibodies against the toxins could reduce this significant and costly public health problem."

"These results highlight the exquisite specificity of monoclonal antibodies and their important role to save lives," said Howard H. Pien, President and CEO of Medarex. "We believe that the strength of our antibody technology platform for generating potentially important treatment options, such as the C. difficile program antibodies, will continue to shape the future of medicine. Furthermore, Medarex's strategy of proving the utility of potentially promising candidates for development by well-designed and well- executed studies is amply demonstrated."

About Clostridium difficile Acquired Diarrhea (CDAD)

C. difficile is a spore forming bacterium that is common in the environment and can colonize the gastrointestinal (GI) tract. It can be easily spread among hospitalized patients and residents of long term care facilities, but also can be found in otherwise healthy individuals in the community. The origin of disease is believed to develop in the presence of antibiotics administered for other infections, in which the complex microbial make up of the GI tract is altered, and C. difficile spores may germinate, grow, and produce toxins A
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Medarex Announces 2008 Third Quarter Financial Results
2. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
5. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
6. Medarex Announces July 10 Live Webcast of R&D Day Event
7. Medarex to Present at the Jefferies Second Annual Healthcare Conference
8. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
9. Medarex to Present at the Bank of America 2008 Healthcare Conference
10. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... (Nasdaq and SWX: BMRN) announced today the appointment,of ... Former Vice President of,Research and Development for Raven ... patents and the recipient of a,collection of prestigious ... Awards from Intellectual Property Owners, Inc., "We ...
... KNDL ), a,leading, global full-service clinical research ... Candace Kendle, PharmD,will participate in the Wachovia 2008 ... Langham Hotel in Boston, Jan. 29-31, 2008. Kendle,s,presentation ... p.m. Eastern Time., (Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ...
... Phytomedics Inc., a clinical,stage biopharmaceutical company developing ... it will present at the,Wachovia 2008 Healthcare Conference ... p.m. ET., Among the topics of the ... and business developments, including Phase III development,activities related ...
Cached Biology Technology:BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 2BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 3Kendle to Present at the Wachovia 2008 Healthcare Conference 2
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... into how a subpopulation of helper T-cells provides immunity ... offer a new means of predicting an AIDS vaccine's ... test these vaccines in clinical trials. , Led by ... the Vaccine Research Center (VRC) at the National Institute ...
... walls. And as with a house, the cell wall needs ... and allow the construction of internal components. A team from ... Research (LICR) has not only shown how the cell gets ... indicate taking away the cell's bricks and mortar is a ...
... St. Louis and their collaborators from Taiwan have examined ... have determined that the crop was domesticated independently at ... Washington University in Arts & Sciences biology doctoral candidate, ... Spencer T. Olin Professor of Biology in Arts & ...
Cached Biology News:AIDS vaccine research offers new insights on survival 2AIDS vaccine research offers new insights on survival 3Biologists find regions of rice domestication 2
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: